Vertex Pharmaceuticals Incorporated Share Price

Equities

VRTX

US92532F1003

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 22/06/2024 am IST 5-day change 1st Jan Change
468.7 USD -0.57% Intraday chart for Vertex Pharmaceuticals Incorporated -2.50% +15.19%
Sales 2024 * 10.75B 898B Sales 2025 * 11.67B 975B Capitalization 121B 10,104B
Net income 2024 * 3.96B 331B Net income 2025 * 4.46B 373B EV / Sales 2024 * 9.95 x
Net cash position 2024 * 13.97B 1,167B Net cash position 2025 * 18.59B 1,553B EV / Sales 2025 * 8.77 x
P/E ratio 2024 *
31.2 x
P/E ratio 2025 *
27.9 x
Employees 5,400
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.9%
More Fundamentals * Assessed data
Dynamic Chart
Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes MT
Vertex Pharmaceuticals Has Pricing Accord for Cystic Fibrosis Drugs With UK National Health Service MT
Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465 MT
Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials MT
Vertex Pharmaceuticals Incorporated Presents Positive Long-Term Data on CASGEVY (Exagamglogene Autotemcel) CI
Vertex Pharmaceuticals Insider Sold Shares Worth $1,089,840, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,483,664, According to a Recent SEC Filing MT
Transcript : Vertex Pharmaceuticals Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM
RBC Adjusts Price Target on Vertex Pharmaceuticals to $421 From $424 MT
Vertex Pharmaceuticals Says Phase 3 Data Show Trikafta Improves Lung Function in Cystic Fibrosis Patients MT
Vertex Pharmaceuticals Incorporated Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA CI
Vertex Pharmaceuticals Insider Sold Shares Worth $1,495,000, According to a Recent SEC Filing MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,000,500, According to a Recent SEC Filing MT
Transcript : Vertex Pharmaceuticals Incorporated Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 04:00 PM
Vertex Pharmaceuticals Insider Sold Shares Worth $2,033,159, According to a Recent SEC Filing MT
More news
1 day-0.57%
1 week-2.50%
Current month+2.94%
1 month+6.04%
3 months+12.75%
6 months+16.99%
Current year+15.19%
More quotes
1 week
463.23
Extreme 463.23
479.15
1 month
435.57
Extreme 435.57
486.43
Current year
391.01
Extreme 391.01
486.43
1 year
335.82
Extreme 335.82
486.43
3 years
176.36
Extreme 176.36
486.43
5 years
165.23
Extreme 165.23
486.43
10 years
64.72
Extreme 64.72
486.43
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 01/17/01
Chairman 68 08/09/08
Director of Finance/CFO 56 10/19/10
Members of the board TitleAgeSince
Director/Board Member 68 08/17/08
Chairman 68 08/09/08
Director/Board Member 64 01/98/01
More insiders
Date Price Change Volume
21/24/21 468.7 -0.57% 2,825,832
20/24/20 471.4 +0.88% 1,409,844
18/24/18 467.3 -1.35% 1,230,804
17/24/17 473.7 -1.46% 1,190,217
14/24/14 480.7 +0.35% 640,792

Delayed Quote Nasdaq, June 22, 2024 at 01:30 am IST

More quotes
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
468.7 USD
Average target price
463.4 USD
Spread / Average Target
-1.13%
Consensus